ReviewFrontiers in veterinary science2023
Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge.
Review in Frontiers in veterinary science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review.Frontiers in veterinary science · 2026Pooled it
- Efficacy and safety of cannabidiol for the treatment of canine osteoarthritis: a systematic review and meta-analysis of animal intervention studies.Frontiers in veterinary science · 2023Pooled it
- Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial.Frontiers in veterinary science · 2025Trial
- Bioactive Compounds and In Vitro Antibacterial Activity of Hemp Leaves and Inflorescences as Potential Functional Feed Ingredients for Canine Nutrition.Animals : an open access journal from MDPI · 2026Article
- Cannabis-Based Nanolipid Formulations for Pain Management.Pharmaceutics · 2026Review
- Sedative and anesthetic-sparing effects of perioperative full-spectrum cannabis oil in female dogs undergoing unilateral mastectomy and ovariohysterectomy.Veterinary research communications · 2026Article
- Plant extracts and phytochemicals in canine and feline mammary cancer models: current evidence and comparative perspectives.Veterinary research communications · 2026Review
- Modulation of the endocannabinoid system reduces inflammatory signalling in canine mammary carcinoma cells.Veterinary record open · 2026Article
- Comparative plasma exposure and fecal excretion of oral cannabidiol in fasted and fed dogs: pilot study.Veterinary research communications · 2026Article
- Plant-Derived Functional Ingredients in Pet Nutrition: Phytochemical Classification, Mechanisms, Efficacy, and Application in Dogs and Cats.Animals : an open access journal from MDPI · 2026Review
- Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum OralAnimals : an open access journal from MDPI · 2026Article
- Oral drug delivery systems for companion animals: an integrative review of medicated treats, chewable tablets, and other pharmaceutical formulations.Brazilian journal of veterinary medicine · 2026Review
- Metabolic effects and pharmacokinetics of oral cannabidiol (CBD) in Connemara ponies following 21 days of treatment.Frontiers in veterinary science · 2026Article
- Incorporating a Behavioral Medicine Approach in the Multi-Modal Management of Chronic Equine Gastric Ulcer Syndrome (EGUS): A Clinical Commentary.Animals : an open access journal from MDPI · 2025Article
- The Role of the Endocannabinoid System in Oncology and the Potential Use of Cannabis Derivatives for Cancer Management in Companion Animals.Animals : an open access journal from MDPI · 2025Review
- Infrared Thermography and Physiological Variables as Methods for Recognizing Fear in Domestic Cats (Veterinary sciences · 2025Article
- Pharmacokinetic Characteristics of a Single Cannabidiol Dose in Oil and Treat Forms and Health Impacts After 30 Days of Administration in Dogs.Animals : an open access journal from MDPI · 2025Article
- A Preliminary Evaluation of the Comparative Efficacy of Gel-Based and Oil-Based CBD on Hematologic and Biochemical Responses in Dogs.Veterinary sciences · 2025Article
- Pharmacokinetics of Non-Psychotropic Phytocannabinoids.Pharmaceutics · 2025Review
- Demographic features, health status, and behavioral changes associated with cannabidiol use in the Dog Aging Project.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last 5 years, interest has grown in using phytocannabinoids, particularly cannabidiol (CBD), in veterinary medicine to treat several pathologies, including pain, epilepsy, anxiety, nausea, anorexia, skin lesions, and even some types of cancer, among others. Indeed, due to a positive perception of CBD use, many pet owners are increasingly requesting this option to relieve their pets, and many veterinarians are exploring this possibility for their patients. Besides the widespread empiric use of CBD in pets, the research is trying to obtain proof of its efficacy and lack of adverse effects and to know its pharmacokinetics to define an appropriate posology. This review summarizes all data published so far about the canine pharmacokinetics, efficacy, and tolerability of CBD and cannabidiolic acid (CBDA). Despite a certain number of available pharmacokinetic studies, the kinetic profile of CBD has yet to be fully known, probably because of the very different experimental conditions. In terms of efficacy, most studies have tested CBD' ability to relieve osteoarthritic pain. In contrast, few studies have evaluated its role in epilepsy, behavioral disorders, and skin lesions. From obtained results, some evidence exists supporting the beneficial role of CBD. Nevertheless, the limited number of published studies and the occurrence of bias in almost all require caution in interpreting findings. From tolerability studies, CBD' side effects can be classified as mild or unremarkable. However, studies were prevalently focused on short- to medium-term treatment, while CBD is usually employed for long-term treatment. Further studies are warranted to define better whether CBD could be a valid adjunct in canine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.